HiFiBiO Therapeutics Closes $75 Million Series D
June 14, 2021
CAMBRIDGE, Mass. & HONG KONG & HANGZHOU, China & SHANGHAI & PARIS–(BUSINESS WIRE)–HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round. The funding was led by the new investor Mirae Asset Financial Group. Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round. The existing shareholders IDG, Sequoia, Legend Star, and Hengxu continued to invest.
For more information on this news posting please click here.